RFA-AI-22-070: Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $150,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 19, 2023.
From the official notice on Grants.gov, last changed December 22, 2022. Checked November 7, 2026.
- Award ceiling$150,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU19
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$250,250
- Typical project length10 years
- U19, Research Program Cooperative Agreement. Several related projects under one award, with substantial NIH involvement. Other open U19 notices.
Projects funded under RFA-AI-22-070 were run by National Institute of Allergy and Infectious Diseases (NIAID, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-22-070 in the NIH Guide.
Key dates
| Posted | December 22, 2022 |
|---|---|
| Deadline | May 19, 2023 |
| Archived by Grants.gov | June 24, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $250,250; it allows up to $150,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the NIAID Autoimmunity Centers of Excellence (ACE), a cooperative network intended to improve the understanding, prevention, and treatment of autoimmune diseases (www.autoimmunitycenters.org). The ACE was founded on the premise that collaborations among basic and clinical scientists can accelerate both fundamental and applied research. The ACE combines Basic and Clinical research programs. This FOA solicits applications for the Basic research program; a companion FOA solicits applications for the Clinical research program. Members of the Basic research program will conduct innovative studies of human autoimmunity within Principal, Pilot, and Collaborative Projects. Members of the Basic and Clinical ACE will work together to design and conduct studies of autoimmune disease pathogenesis and mechanisms of action of immune-modulating interventions being tested in ACE clinical trials.
Funded under RFA-AI-22-070 so far
NIH funded 5 projects under RFA-AI-22-070 in fiscal 2024 to 2026, at 5 institutions. The median yearly award was $250,250.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| An autoimmune center of excellence for the study of IgG4-related disease | Massachusetts General Hospital | 2026 | $667,334 |
| Administrative Core | Feinstein Institute for Medical Research | 2026 | $51,582 |
| Regulation of B cell Responses in SLE and Other Autoimmune Diseases | Emory University | 2026 | $78,250 |
| UCLA ACE Administrative Core | University of California Los Angeles | 2026 | $78,750 |
| Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity | Weill Medical Coll of Cornell Univ | 2026 | $685,319 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-22-070 still open?
No. It closed on May 19, 2023.
Who can apply for Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed)?
Closed May 19, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $150,000 each.
Who has been funded under RFA-AI-22-070?
NIH RePORTER lists 5 projects funded under RFA-AI-22-070 in fiscal 2024 to 2026, at 5 institutions. The most were at Massachusetts General Hospital, Feinstein Institute for Medical Research, Emory University.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional)
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
- Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)
- National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)